-葡萄糖共载体2抑制剂对神经系统疾病的影响:系统性审查和元分析
Bo Xu1,2,3,4,5, Mingxia Yang1,2,3,4, Shaoqian Li1,2,3,4,6
1The First Affiliated Hospital, Hunan Provincial Clinical Medical Research Center for Drug Evaluation of Major Chronic Diseases, Hengyang Medical School, University of South China, Hengyang, China.
-葡萄糖共运输体2 (SGLT2) 抑制剂对2型糖尿病成年人大多数神经系统疾病没有显著影响. 然而,在特定人群中,人们注意到帕金森病的风险降低,某些药物会增加昏和动脉问题的风险.
科学领域:
- 神经学 神经学
- 内分泌学 在内分泌学.
- 心脏病学 心脏病学
背景情况:
- 患有2型糖尿病 (T2DM) 的成年人面临大脑和精神疾病的风险增加,常常由慢性脏病或心力衰竭加剧.
- -葡萄糖共运输体2 (SGLT2) 抑制剂对这些神经和精神疾病风险的影响尚不清楚.
研究的目的:
- 系统地审查和元分析SGLT2抑制剂对神经系统疾病的影响.
- 评估SGLT2抑制剂与相关患者群体中各种神经疾病之间的关联.
主要方法:
- 至少持续24周的随机,双盲,安慰剂对照试验 (RCT) 的系统综述和元分析.
- 搜索了包括PubMed,ClinicalTrials.gov和Web of Science.gov在内的数据库.
- 采用Mantle-Haenszel统计方法,风险比率 (RR) 和二分法变量的95%置信区间 (CI).
主要成果:
- 对52篇出版物/试验与111,376名参与者的分析显示,SGLT2抑制剂对缺血性中风,脑血管事故,痴呆症,动脉封闭/缩小症,出血性中风或短暂缺血性发作没有显著影响.
- 在心力衰竭小组中观察到对帕金森病的轻微风险降低.
- 恩帕格利弗洛辛和达帕格利弗洛辛分别与昏睡和动脉闭塞/缩小症的风险增加有关.
结论:
- 一般来说,SGLT2抑制剂对T2DM患者中主要神经系统疾病的风险没有显著的影响.
- 在特定的子组中注意到降低帕金森病风险的潜在益处.
- 临床医生应该意识到,使用特定的SGLT2抑制剂,如empagliflozin和dapagliflozin,可能会增加昏和动脉问题的风险.
更多相关视频
10:08Study of the Functions and Activities of Neuronal K-Cl Co-Transporter KCC2 Using Western Blotting
Published on: December 9, 2022
07:29Real-time Analysis of Gut-brain Neural Communication: Cortex wide Calcium Dynamics in Response to Intestinal Glucose Stimulation
Published on: December 29, 2023
相关概念视频
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Secondary Active Transport
Disorders of the Nervous Tissue
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Glucose Absorption Into the Small Intestine
Ligand-Gated Ion Channel Receptor: Gating Mechanism
